Spectroscopic, structural characterizations and antioxidant capacity of the chromium (III) niacinamide compound as a diabetes mellitus drug model

• Published in: Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy Vol. 173; pp. 122 - 131
• Main Authors: Refat, Moamen S., El-Megharbel, Samy M., Hussien, M.A., Hamza, Reham Z., Al-Omar, Mohamed A., Naglah, Ahmed M., Afifi, Walid M., Kobeasy, Mohamed I.
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 15-02-2017
• Subjects: Chromium; Diabetes; Niacinamide; Spectral studies; Chromium; Niacinamide; Spectral studies; Diabetes
• ISSN: 1386-1425
• DOI: 10.1016/j.saa.2016.08.053

New binuclear chromium (III) niacinamide compound with chemical formula [Cr2(Nic)(Cl)6(H2O)4]·H2O was obtained upon the reaction of chromium (III) chloride with niacinamide (Nic) in methanol solvent at 60°C. The proposed structure was discussed with the help of microanalytical analyses, conductivity, spectroscopic (FT-IR and UV–vis.), magnetic calculations, thermogravimetric analyses (TG/TGA), and morphological studies (X-ray of solid powder and scan electron microscopy. The infrared spectrum of free niacinamide in comparison with its chromium (III) compound indicated that the chelation mode occurs via both nitrogen atoms of pyridine ring and primary –NH2 group. The efficiency of chromium (III) niacinamide compound in decreasing of glucose level of blood and HbA1c in case of diabetic rats was checked. The ameliorating gluconeogenic enzymes, lipid profile and antioxidant defense capacities are considered as an indicator of the efficiency of new chromium (III) compound as antidiabetic drug model.
[Display omitted]
•New chromium (III) niacinamide compound was prepared in neutral media.•The suggested Cr(III) complex was assigned based on micro-analytical and spectroscopic analyses.•The morphological surface was checked using XRD and SEM.•The coordination behavior take place around Cr(III) ion through nitrogen atoms of pyridine ring and NH2 group.•This complex make to decrease the blood glucose level against diabetic rats.